問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王閔宏

Recruiting

List

37Cases

2020-07-20 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2022-09-01 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2023-05-01 - 2034-07-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2023-06-01 - 2028-03-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)

  • Condition/Disease

    Gastrointestinal Neoplasms

  • Test Drug

    IDRX-42 (GSK6042981) Sunitinib

Participate Sites
6Sites

Recruiting6Sites

2025-09-01 - 2027-05-31

Phase I/II

Active
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients with Advanced Gastric and Gastroesophageal Cancer

  • Condition/Disease

    Gastric Cancer Adenocarcinoma Metastatic Gastroesophageal Adenocarcinoma

  • Test Drug

    BDC-4182

Participate Sites
6Sites

Recruiting6Sites

2024-05-01 - 2028-12-22

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2024-06-28 - 2028-05-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2024-06-28 - 2028-03-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

2026-05-01 - 2034-12-31

Phase III

Active
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

  • Condition/Disease

    Myelodysplastic Syndrome、 Anemia

  • Test Drug

    皮下注射劑

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB